Sergey N. Shilov
Novosibirsk, NVS, Russian Federation
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
Tetranectin as a potential novel prognostic biomarker in anthracycline-related cardiac dysfunction.
Journal: Heart and vessels
Published: March 24, 2023
Serum Cytokines as Biomarkers in Heart Failure with Preserved Ejection Fraction and Sleep Apnea: A Prospective Cohort Study.
Journal: Life (Basel, Switzerland)
Published: February 01, 2023
Anthra-cycline-Induced Cardiotoxicity: the Role of Genetic Predictors
Journal: Kardiologiia
Published: November 23, 2021
Extracellular matrix remodeling in anthracycline-induced cardiotoxicity: What place on the pedestal?
Extracellular matrix remodeling in anthracycline-induced cardiotoxicity: What place on the pedestal?
Journal: International journal of cardiology
Published: November 18, 2021
Heart failure with preserved left ventricular ejection fraction in patients with obstructive sleep apnea syndrome: prognostic value of biomarkers.
Journal: Kardiologiia
Published: March 15, 2021
Anthracycline-Induced Cardiotoxicity: The Role of Endothelial Dysfunction.
Journal: Cardiology
Published: April 19, 2020
The effect of bisphosphonate therapy on reducing the risk of cardiovascular complications associated with chronic heart failure, type 2 diabetes and osteoporosis in postmenopausal women
Journal: Terapevticheskii arkhiv
Published: April 16, 2020
Prognostic role of p53 gene polymorphism in risk assessment of anthracycline-induced cardiotoxicity
Journal: Kardiologiia
Published: August 22, 2019
Pathogenetic and Prognostic Role of Growth Factors in the Development of Chronic Heart Failure
Journal: Kardiologiia
Published: December 26, 2017
Role of soluble Fas ligand in myocardial remodeling, severity and outcomes of chronic heart failure
Journal: Terapevticheskii arkhiv
Published: October 14, 2016
Last Updated: 09/26/2026